NTS-521
/ NeuroTrauma Sci
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 04, 2026
ACT-IVATE: A Phase 2a Study to Evaluate the Dose-response, Safety, Tolerability, Efficacy, and Population Pharmacokinetics of Intravenous NTS-521 Infusions in the Early Recovery Treatment From Acute Ischemic Stroke
(clinicaltrials.gov)
- P2 | N=140 | Not yet recruiting | Sponsor: NeuroTrauma Sciences, LLC
New P2 trial • Cardiovascular • Ischemic stroke
1 to 1
Of
1
Go to page
1